マーケットレポート詳細
バイオシミラーの世界市場：製品別、適応症別2026年予測
Biosimilars Market by Product (Monoclonal antibodies (infliximab, rituximab, trastuzumab), Insulin, Interferon, Etanercept, Glucagon, Calcitonin), Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2026
- 出版元：MarketsandMarkets 出版元について
- 発行年：2021年10月
- 定価 ：Single User License(1名様ライセンス)US$5,650(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文224ページになります。
- 商品コード：MAM2670
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
バイオシミラーの世界市場規模は2021年に推計156億ドル、2026年には447億ドルへ拡大するとレポートは予測しています。レポートはバイオシミラーの世界市場について2026年までの市場予測データ(金額US$)を掲載しています。また市場をさまざまな切り口で細分化し、そのセグメント市場ごとの市場予測を中心に構成されています。当レポートでの各種セグメント市場の区分は、製品別市場、適応症別市場、および主要国地域別市場、などとなっています。また競合状況、主要企業情報（15社）、COVID-19による影響、バリューチェーン分析などの分析情報も加味し、バイオシミラー市場の今後成長性および動向を詳細にレポートしています。
【レポート構成概要】
◆バイオシミラーの世界市場予測2019-2026年
・市場規模(US$)
◆製品別、市場-2026年
モノクローナル抗体
・インフリキシマブ
・トラスツズマブ
・リツキシマブ
・アダリムマブ
・その他モノクローナル抗体
インスリン
顆粒球コロニー刺激因子
エリスロポエチン
組換えヒト成長ホルモン
エタネルセプト
卵胞刺激ホルモン
テリパラチド
インターフェロン
エノキサパリンナトリウム
グルカゴン
カルシトニン
※(市場規模US$)
◆適応症別、市場-2026年
・腫瘍学
・炎症性および自己免疫疾患
・慢性疾患
・血液疾患
・成長ホルモン欠乏症
・感染症
・その他適応症
※(市場規模US$)
◆主要国地域別市場-2026年
欧州
・英国、フランス、ドイツ、イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド、韓国、オーストラリア
・その他アジア太平洋
北米
・米国、カナダ
中南米
中東アフリカ
※国地域別に全セグメント別の細分化データ掲載、詳細は目次参照
◆市場分析
・市場ダイナミクス（ドライバー、障壁、機会、課題）
・COVID-19による影響
・バリューチェーン分析
・サプライチェーン分析
・ファイブフォース分析
・市場シェア分析
・競合状況
◆バイオシミラーの主要企業プロフィール動向
・NOVARTIS AG
・PFIZER INC.
・DR. REDDY’S LABORATORIES LTD.
・AMGEN INC.
・ELI LILLY AND COMPANY
・TEVA PHARMACEUTICAL INDUSTRIES LTD.
・FRESENIUS SE & CO. KGAA
・STADA ARZNEIMITTEL AG
・BOEHRINGER INGELHEIM
・GEDEON RICHTER PLC
・CELLTRION
・SAMSUNG BIOLOGICS
・COHERUS BIOSCIENCES
・BIOCON LIMITED
・VIATRIS
（その他企業）
・AMEGA BIOTECH
・APOTEX INC.
・BIOCAD
・MABXIENCE
・PROBIOMED S.A. DE C.V.
・協和キリン富士フイルムバイオロジクス株式会社
・INTAS PHARMACEUTICALS LTD.
・THERAMEX
・RELIANCE LIFE SCIENCES
・KASHIV BIOSCIENCES
（全224頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1.... INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
・ TABLE 1........... BIOSIMILARS MARKET: INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED.. 28
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 LIMITATIONS
1.7 SUMMARY OF CHANGES
2.... RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
・ FIGURE 1.................................................. RESEARCH DESIGN.. 31
2.2 SECONDARY DATA
・ FIGURE 2.............................................. SECONDARY SOURCES.. 32
2.3 PRIMARY DATA
・ FIGURE 3............................. KEY DATA FROM PRIMARY SOURCES
・ FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
・ FIGURE 5.......................... DATA TRIANGULATION METHODOLOGY
2.5 MARKET ESTIMATION METHODOLOGY
2.5.1 BOTTOM-UP APPROACH
2.5.2 TOP-DOWN APPROACH.. 36
・ FIGURE 6.............................................. TOP-DOWN APPROACH.. 36
・ FIGURE 7. BIOSIMILARS MARKET: FINAL MARKET SIZE (USD BILLION)
2.6 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
2.7 INSIGHTS FROM PRIMARIES
・ FIGURE 8............... MARKET VALIDATION FROM PRIMARY EXPERTS
2.8 RESEARCH ASSUMPTIONS
2.9 LIMITATIONS
2.10 RISK ASSESSMENT
3.... EXECUTIVE SUMMARY
・ FIGURE 9 BIOSIMILARS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
・ FIGURE 10... BIOSIMILARS MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
・ FIGURE 11. BIOSIMILARS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)
4.... PREMIUM INSIGHTS
4.1 BIOSIMILARS MARKET OVERVIEW
・ FIGURE 12...... RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT AND COUNTRY (2020)
・ FIGURE 13......... INSULIN HELD THE LARGEST SHARE OF THE NORTH AMERICAN BIOSIMILARS MARKET IN 2020
4.3 GEOGRAPHICAL SNAPSHOT OF THE BIOSIMILARS MARKET
・ FIGURE 14......... ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
5.... MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
・ FIGURE 15............. BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
5.2.1 DRIVERS
5.2.1.1 INCREASING DEMAND FOR BIOSIMILAR DRUGS DUE TO THEIR COST-EFFECTIVENESS
5.2.1.2 RISING GERIATRIC POPULATION AND THE INCREASING INCIDENCE OF CHRONIC DISEASES
・ FIGURE 16. GERIATRIC POPULATION, BY REGION, 2020 VS. 2030 VS. 2050 (MILLION)
・ FIGURE 17 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
5.2.1.3 ABBREVIATED REGULATORY APPROVAL PROCESS AND CONCEPT OF INTERCHANGEABILITY
・ FIGURE 18 COMPARISON OF REFERENCE PRODUCTS, BIOSIMILARS, AND INTERCHANGEABLE PRODUCTS
5.2.2 RESTRAINTS
5.2.2.1 COMPLEXITIES IN MANUFACTURING
5.2.2.2 RESISTANCE FROM BIOLOGICS MANUFACTURERS
5.2.3 OPPORTUNITIES
5.2.3.1 EMERGING MARKETS
5.2.3.2 PATENT EXPIRY OF BLOCKBUSTER BIOLOGICS AND RESEARCH ON NEW INDICATIONS
・ TABLE 2....... LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY
5.2.4 CHALLENGES
5.2.4.1 EXCESS COMPETITION
5.2.5 TRENDS
5.2.5.1 COLLABORATIONS FOR BIOSIMILAR RESEARCH AND CLINICAL TRIALS
・ TABLE 3..... MAJOR COLLABORATIONS IN THE BIOSIMILARS MARKET (2017–2020)
5.3 COVID-19 IMPACT ANALYSIS
5.4 TECHNOLOGY ANALYSIS
・ TABLE 4. COMPARISON OF ORIGINAL BIOLOGICS WITH BIOSIMILARS
・ TABLE 5................................. GENERIC DRUGS VS. BIOSIMILARS
5.5 VALUE CHAIN ANALYSIS
・ FIGURE 19................... VALUE CHAIN ANALYSIS FOR BIOSIMILARS
5.6 ECOSYSTEM MARKET MAP
・ FIGURE 20............... ECOSYSTEM MARKET MAP FOR BIOSIMILARS
5.7 SUPPLY CHAIN ANALYSIS
5.8 PORTER’S FIVE FORCES ANALYSIS
・ TABLE 6............ PORTER’S FIVE FORCES: IMPACT ANALYSIS ON THE BIOSIMILARS MARKET
5.8.1 THREAT FROM NEW ENTRANTS
5.8.2 THREAT FROM SUBSTITUTES
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 BARGAINING POWER OF BUYERS
5.8.5 INTENSITY OF COMPETITION RIVALRY
5.9 REGULATORY LANDSCAPE
・ TABLE 7... REGULATORY LANDSCAPE FOR THE BIOSIMILARS MARKET
6.... BIOSIMILARS MARKET, BY PRODUCT
6.1 INTRODUCTION
・ FIGURE 21 BIOSIMILARS APPROVED IN THE US, EUROPE, AND CHINA, BY TYPE
・ TABLE 8...... BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
6.2 MONOCLONAL ANTIBODIES
・ TABLE 9.. BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2019–2026 (USD MILLION)
・ TABLE 10 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION,
2019–2026 (USD MILLION)
6.2.1 INFLIXIMAB
6.2.1.1 INFLIXIMAB ACCOUNTED FOR THE LARGEST SHARE OF THE MONOCLONAL ANTIBODIES MARKET
・ TABLE 11......... BIOSIMILARS MARKET FOR INFLIXIMAB, BY REGION,
2019–2026 (USD MILLION)
6.2.2 TRASTUZUMAB
6.2.2.1 RISING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
・ TABLE 12.... BIOSIMILARS MARKET FOR TRASTUZUMAB, BY REGION,
2019–2026 (USD MILLION)
6.2.3 RITUXIMAB
6.2.3.1 RISING INCIDENCE OF AUTOIMMUNE DISEASES AND CANCER ARE KEY DRIVERS FOR MARKET GROWTH
・ TABLE 13......... BIOSIMILARS MARKET FOR RITUXIMAB, BY REGION,
2019–2026 (USD MILLION)
6.2.4 ADALIMUMAB
6.2.4.1 ADALIMUMAB TO REGISTER THE HIGHEST CAGR IN THE MONOCLONAL ANTIBODIES MARKET
・ TABLE 14..... BIOSIMILARS MARKET FOR ADALIMUMAB, BY REGION,
2019–2026 (USD MILLION)
6.2.5 OTHER MONOCLONAL ANTIBODIES
・ TABLE 15............ BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
6.3 INSULIN
6.3.1 INCREASING INCIDENCE OF DIABETES TO SUPPORT MARKET GROWTH
・ TABLE 16............. BIOSIMILARS MARKET FOR INSULIN, BY REGION,
2019–2026 (USD MILLION)
6.4 GRANULOCYTE COLONY-STIMULATING FACTOR
6.4.1 G-CSF IS USED TO TREAT CANCER PATIENTS WITH NEUTROPENIA OCCURRING AFTER CHEMOTHERAPY
・ TABLE 17.................. LIST OF APPROVED BIOSIMILARS FOR G-CSF
・ TABLE 18......... BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2019–2026 (USD MILLION)
6.5 ERYTHROPOIETIN
6.5.1 RISING INCIDENCE OF BLOOD DISORDERS WILL DRIVE MARKET GROWTH
・ TABLE 19.... LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN
・ TABLE 20. BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION,
2019–2026 (USD MILLION)
6.6 RECOMBINANT HUMAN GROWTH HORMONE
6.6.1 MARKET GROWTH IS DRIVEN PRIMARILY BY THE INCREASING INCIDENCE OF GROWTH DEFICIENCY DISORDERS
・ TABLE 21.......... BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE,
BY REGION, 2019–2026 (USD MILLION)
6.7 ETANERCEPT
6.7.1 APAC TO WITNESS THE HIGHEST GROWTH IN THE ETANERCEPT MARKET DURING THE FORECAST PERIOD
・ TABLE 22....... BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION,
2019–2026 (USD MILLION)
6.8 FOLLITROPIN
6.8.1 INCREASING APPLICATION OF FOLLITROPIN IN INFERTILITY TREATMENT TO DRIVE MARKET GROWTH
・ TABLE 23....... BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION,
2019–2026 (USD MILLION)
6.9 TERIPARATIDE
6.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS IS THE MAJOR FACTOR DRIVING MARKET GROWTH
・ TABLE 24..... BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION,
2019–2026 (USD MILLION)
6.10 INTERFERONS
6.10.1 RISING INCIDENCE OF INFECTIOUS DISEASES TO
SUPPORT MARKET GROWTH
・ TABLE 25..... BIOSIMILARS MARKET FOR INTERFERONS, BY REGION,
2019–2026 (USD MILLION)
6.11 ENOXAPARIN SODIUM
6.11.1 WIDE RANGE OF APPLICATIONS HAVE SUPPORTED THE DEMAND FOR ENOXAPARIN SODIUM BIOSIMILARS.. 76
・ TABLE 26....... BIOSIMILARS MARKET FOR ENOXAPARIN SODIUM, BY REGION,
2019–2026 (USD MILLION)
6.12 GLUCAGON
6.12.1 SANDOZ IS A MAJOR PLAYER IN THE GLUCAGON BIOSIMILARS MARKET
・ TABLE 27......... BIOSIMILARS MARKET FOR GLUCAGON, BY REGION,
2019–2026 (USD MILLION)
6.13 CALCITONIN
6.13.1 INCREASING INCIDENCE OF OSTEOPOROSIS TO DRIVE MARKET GROWTH
・ TABLE 28........ BIOSIMILARS MARKET FOR CALCITONIN, BY REGION,
2019–2026 (USD MILLION)
7.... BIOSIMILARS MARKET, BY INDICATION
7.1 INTRODUCTION
・ TABLE 29. BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
7.2 ONCOLOGY
7.2.1 RISING BURDEN OF CANCER TO DRIVE THE DEMAND FOR BIOSIMILARS
・ FIGURE 22.................... CANCER CASES, BY TYPE, 2020 (MILLION)
・ FIGURE 23........ DEATHS DUE TO CANCER, BY TYPE, 2020 (MILLION)
・ TABLE 30.................. BIOSIMILARS APPROVED BY THE US FDA FOR ONCOLOGICAL INDICATIONS, 2018-2020
・ FIGURE 24. ARTICLES PUBLISHED ON BIOSIMILARS FOR ONCOLOGY, 2012–2020
・ TABLE 31......... BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION,
2019–2026 (USD MILLION)
7.3 INFLAMMATORY & AUTOIMMUNE DISEASES
7.3.1 CHANGES IN LIFESTYLE AND ENVIRONMENTAL CONDITIONS HAVE INCREASED THE INCIDENCE OF INFLAMMATORY & AUTOIMMUNE DISEASES
・ TABLE 32............. BIOSIMILARS MARKET FOR INFLAMMATORY AND AUTOIMMUNE DISEASES, BY REGION, 2019–2026 (USD MILLION). 85
7.4 CHRONIC DISEASES
7.4.1 HIGH BURDEN OF CVD & DIABETES WORLDWIDE TO DRIVE MARKET GROWTH
・ TABLE 33..... BIOSIMILARS APPROVED BY THE US FDA FOR CHRONIC DISEASES,
2018–2020
・ TABLE 34......... BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION,
2019–2026 (USD MILLION)
7.5 BLOOD DISORDERS
7.5.1 INCREASING INCIDENCE OF BLOOD DISORDERS HAS INCREASED THE DEMAND FOR BIOSIMILARS FOR THIS INDICATION SEGMENT
・ TABLE 35.......... BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION,
2019–2026 (USD MILLION)
7.6 GROWTH HORMONE DEFICIENCY
7.6.1 GROWING USE OF BIOSIMILARS FOR THE TREATMENT OF THIS MEDICAL CONDITION TO SUPPORT MARKET GROWTH
・ TABLE 36.............. BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2019–2026 (USD MILLION)
7.7 INFECTIOUS DISEASES
7.7.1 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES IS EXPECTED TO BE THE HIGHEST IN THE ASIA PACIFIC
・ TABLE 37...... BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION,
2019–2026 (USD MILLION)
7.8 OTHER INDICATIONS
・ TABLE 38......... BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION,
2019–2026 (USD MILLION)
8.... BIOSIMILARS MARKET, BY REGION
8.1 INTRODUCTION
・ FIGURE 25............. BIOSIMILARS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
・ TABLE 39...... BIOSIMILARS MARKET, BY REGION, 2019–2026 (USD MILLION)
8.2 EUROPE
・ TABLE 40.................. LIST OF BIOSIMILARS APPROVED IN EUROPE
・ FIGURE 26................. EUROPE: BIOSIMILARS MARKET SNAPSHOT
・ TABLE 41 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 42 EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
・ TABLE 43......... EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION). 97
・ TABLE 44............. EUROPE: BIOSIMILARS MARKET, BY INDICATION,
2019–2026 (USD MILLION)
8.2.1 UK
8.2.1.1 THE UK HOLDS THE LARGEST SHARE OF THE BIOSIMILARS MARKET IN EUROPE
・ TABLE 45................................... LIST OF BIOSIMILARS IN THE UK
・ TABLE 46...... UK: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
・ TABLE 47................ UK: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2019–2026 (USD MILLION)
・ TABLE 48... UK: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
8.2.2 FRANCE
8.2.2.1 RISING GERIATRIC POPULATION WILL DRIVE MARKET GROWTH
・ TABLE 49 FRANCE: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
・ TABLE 50......... FRANCE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION). 101
・ TABLE 51............. FRANCE: BIOSIMILARS MARKET, BY INDICATION,
2019–2026 (USD MILLION)
8.2.3 GERMANY
8.2.3.1 PRESENCE OF A FAVORABLE PRICING SYSTEM HAS SUPPORTED BIOSIMILAR ADOPTION IN GERMANY
・ TABLE 52.... GERMANY: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
・ TABLE 53....... GERMANY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION). 103
・ TABLE 54........... GERMANY: BIOSIMILARS MARKET, BY INDICATION,
2019–2026 (USD MILLION)
8.2.4 ITALY
8.2.4.1 RISING GERIATRIC POPULATION IN ITALY WILL SUPPORT THE ADOPTION OF BIOSIMILARS IN THE COUNTRY
・ TABLE 55... ITALY: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
・ TABLE 56............. ITALY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 57 ITALY: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
8.2.5 SPAIN
8.2.5.1 PATIENT INCENTIVES TO PROMOTE BIOSIMILAR USE IS A KEY GROWTH DRIVER FOR THE BIOSIMILARS MARKET IN SPAIN
・ TABLE 58.. SPAIN: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
・ TABLE 59............ SPAIN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 60 SPAIN: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
8.2.6 REST OF EUROPE
・ TABLE 61.... ROE: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
・ TABLE 62.............. ROE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 63.. ROE: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
8.3 ASIA PACIFIC
・ FIGURE 27........... ASIA PACIFIC: BIOSIMILARS MARKET SNAPSHOT
・ TABLE 64......... ASIA PACIFIC: BIOSIMILARS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
・ TABLE 65......... ASIA PACIFIC: BIOSIMILARS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)
・ TABLE 66... ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 67....... ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION,
2019–2026 (USD MILLION)
8.3.1 INDIA
8.3.1.1 INDIA HELD THE LARGEST SHARE OF THE APAC BIOSIMILARS MARKET
・ TABLE 68........... BIOSIMILARS APPROVED AND MARKETED IN INDIA
・ TABLE 69.. INDIA: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
・ TABLE 70............ INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 71 INDIA: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
8.3.2 CHINA
8.3.2.1 CHINA IS THE FASTEST-GROWING MARKET FOR BIOSIMILARS IN THE APAC
・ TABLE 72............................... BIOSIMILARS APPROVED IN CHINA
・ TABLE 73. CHINA: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
・ TABLE 74........... CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 75...... CHINA: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
8.3.3 SOUTH KOREA
8.3.3.1 FAVORABLE GOVERNMENT INITIATIVES TO DRIVE THE MARKET IN SOUTH KOREA
・ TABLE 76........... LIST OF BIOSIMILARS APPROVED IN SOUTH KOREA
・ TABLE 77........ SOUTH KOREA: BIOSIMILARS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)
・ TABLE 78. SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 79..... SOUTH KOREA: BIOSIMILARS MARKET, BY INDICATION,
2019–2026 (USD MILLION)
8.3.4 JAPAN
8.3.4.1 LARGE GERIATRIC POPULATION IN THE COUNTRY TO DRIVE MARKET GROWTH
・ TABLE 80..................... LIST OF BIOSIMILARS APPROVED IN JAPAN
・ TABLE 81. JAPAN: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
・ TABLE 82........... JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 83...... JAPAN: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
8.3.5 AUSTRALIA
8.3.5.1 INCREMENTAL CHANGES IN BIOSIMILAR REGULATIONS AND INCREASING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH
・ TABLE 84............... LIST OF BIOSIMILARS APPROVED IN AUSTRALIA
・ TABLE 85............ AUSTRALIA: BIOSIMILARS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)
・ TABLE 86..... AUSTRALIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 87......... AUSTRALIA: BIOSIMILARS MARKET, BY INDICATION,
2019–2026 (USD MILLION)
8.3.6 REST OF ASIA PACIFIC
・ TABLE 88........... LIST OF BIOSIMILARS APPROVED IN NEW ZEALAND
・ TABLE 89................ LIST OF BIOSIMILARS APPROVED IN MALAYSIA
・ TABLE 90.............. LIST OF BIOSIMILARS APPROVED IN SINGAPORE
・ TABLE 91...... ROAPAC: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
・ TABLE 92......... ROAPAC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION). 132
・ TABLE 93............. ROAPAC: BIOSIMILARS MARKET, BY INDICATION,
2019–2026 (USD MILLION)
8.4 NORTH AMERICA
・ TABLE 94..... NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
・ TABLE 95.... NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)
・ TABLE 96................. NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION). 134
・ TABLE 97.. NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION,
2019–2026 (USD MILLION)
8.4.1 US
8.4.1.1 THE US DOMINATES THE NORTH AMERICAN BIOSIMILARS MARKET
・ TABLE 98.................... LIST OF BIOSIMILARS APPROVED IN THE US
・ TABLE 99...... US: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
・ TABLE 100.............. US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2019–2026 (USD MILLION)
・ TABLE 101.. US: BIOSIMILARS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
8.4.2 CANADA
8.4.2.1 FAVORABLE GOVERNMENT INITIATIVES TO SUPPORT MARKET GROWTH
・ TABLE 102................ LIST OF BIOSIMILARS APPROVED IN CANADA
・ TABLE 103.... CANADA: BIOSIMILARS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
・ TABLE 104....... CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION). 140
・ TABLE 105........... CANADA: BIOSIMILARS MARKET, BY INDICATION,
2019–2026 (USD MILLION)
8.5 LATIN AMERICA
8.5.1 RISING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
・ TABLE 106....... LIST OF BIOSIMILARS APPROVED IN LATIN AMERICA
・ TABLE 107.... LATIN AMERICA: BIOSIMILARS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)
・ TABLE 108................. LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 109.. LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION,
2019–2026 (USD MILLION)
8.6 MIDDLE EAST AND AFRICA
8.6.1 FAVORABLE REGULATORY REFORMS AND INFRASTRUCTURAL DEVELOPMENT TO FAVOR MARKET GROWTH
・ TABLE 110..... MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)
・ TABLE 111... MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION). 144
・ TABLE 112..... MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY INDICATION,
2019–2026 (USD MILLION)
9.... COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 RIGHT-TO-WIN APPROACH
・ FIGURE 28........ KEY DEVELOPMENTS OF MAJOR PLAYERS, JANUARY 2018–AUGUST 2021
9.3 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS
・ FIGURE 29 REVENUE ANALYSIS FOR KEY COMPANIES OVER THE PAST THREE YEARS
9.4 MARKET SHARE ANALYSIS
・ FIGURE 30. GLOBAL BIOSIMILARS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
9.5 COMPANY EVALUATION QUADRANT
9.5.1 STARS
9.5.2 EMERGING LEADERS.. 150
9.5.3 PERVASIVE PLAYERS.. 150
9.5.4 PARTICIPANTS
・ FIGURE 31............. BIOSIMILARS MARKET: COMPANY EVALUATION QUADRANT, 2020
9.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
9.6.1 PROGRESSIVE COMPANIES
9.6.2 STARTING BLOCKS
9.6.3 RESPONSIVE COMPANIES
9.6.4 DYNAMIC COMPANIES
・ FIGURE 32............. BIOSIMILARS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
9.7 COMPETITIVE BENCHMARKING
9.7.1 COMPANY PRODUCT FOOTPRINT
9.7.2 COMPANY INDICATION FOOTPRINT
9.7.3 COMPANY REGIONAL FOOTPRINT
9.8 GROWTH STRATEGIES ADOPTED BY EMERGING AND KEY PLAYERS
9.8.1 PRODUCT LAUNCHES & APPROVALS
9.8.2 DEALS
9.8.3 OTHER DEVELOPMENTS
10.. COMPANY PROFILES
10.1 MAJOR PLAYERS
(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, AND MNM VIEW (KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, AND WEAKNESSES AND COMPETITIVE THREATS))*
10.1.1 NOVARTIS AG
・ TABLE 113........................... NOVARTIS AG: BUSINESS OVERVIEW
・ FIGURE 33....................... SANDOZ: COMPANY SNAPSHOT (2020)
10.1.2 PFIZER INC.
・ TABLE 114.............................. PFIZER INC: BUSINESS OVERVIEW
・ FIGURE 34................... PFIZER INC.: COMPANY SNAPSHOT (2020)
10.1.3 DR. REDDY’S LABORATORIES LTD.
・ TABLE 115....... DR. REDDY’S LABORATORIES: BUSINESS OVERVIEW
・ FIGURE 35 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2020)
10.1.4 AMGEN INC.
・ TABLE 116............................. AMGEN INC.: BUSINESS OVERVIEW
・ FIGURE 36.................. AMGEN INC.: COMPANY SNAPSHOT (2020)
10.1.5 ELI LILLY AND COMPANY
・ TABLE 117............. ELI LILLY AND COMPANY: BUSINESS OVERVIEW
・ FIGURE 37... ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2020)
10.1.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.
・ TABLE 118..... TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
・ FIGURE 38..... TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2020)
10.1.7 FRESENIUS SE & CO. KGAA
・ TABLE 119.......... FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW
・ FIGURE 39 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2020)
10.1.8 STADA ARZNEIMITTEL AG
・ TABLE 120................. STADA ARZNEIMITTEL: BUSINESS OVERVIEW
・ FIGURE 40....... STADA ARZNEIMITTEL: COMPANY SNAPSHOT (2020)
10.1.9 BOEHRINGER INGELHEIM
・ TABLE 121............ BOEHRINGER INGELHEIM: BUSINESS OVERVIEW
・ FIGURE 41.. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2020)
10.1.10 GEDEON RICHTER PLC
・ TABLE 122................ GEDEON RICHTER PLC: BUSINESS OVERVIEW
・ FIGURE 42...... GEDEON RICHTER PLC: COMPANY SNAPSHOT (2020)
10.1.11 CELLTRION
・ TABLE 123.............................. CELLTRION: BUSINESS OVERVIEW
・ FIGURE 43.................... CELLTRION: COMPANY SNAPSHOT (2020)
10.1.12 SAMSUNG BIOLOGICS
・ TABLE 124................ SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
・ FIGURE 44..... SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2020)
10.1.13 COHERUS BIOSCIENCES
・ TABLE 125............. COHERUS BIOSCIENCES: BUSINESS OVERVIEW
・ FIGURE 45... COHERUS BIOSCIENCES: COMPANY SNAPSHOT (2020)
10.1.14 BIOCON LIMITED
・ TABLE 126....................... BIOCON LIMITED: BUSINESS OVERVIEW
・ FIGURE 46............. BIOCON LIMITED: COMPANY SNAPSHOT (2020)
10.1.15 VIATRIS
・ TABLE 127................................... VIATRIS: BUSINESS OVERVIEW
10.2 OTHER PLAYERS
10.2.1 AMEGA BIOTECH
・ TABLE 128....................... AMEGA BIOTECH: BUSINESS OVERVIEW
10.2.2 APOTEX INC.
・ TABLE 129............................. APOTEX INC.: BUSINESS OVERVIEW
10.2.3 BIOCAD
・ TABLE 130.................................. BIOCAD: BUSINESS OVERVIEW
10.2.4 MABXIENCE
・ TABLE 131............................. MABXIENCE: BUSINESS OVERVIEW
10.2.5 PROBIOMED S.A. DE C.V.
・ TABLE 132............................ PROBIOMED: BUSINESS OVERVIEW
10.2.6 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.
・ TABLE 133 FUJIFILM KYOWA KIRIN BIOLOGICS: BUSINESS OVERVIEW
10.2.7 INTAS PHARMACEUTICALS LTD.
・ TABLE 134.... INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
10.2.8 THERAMEX
・ TABLE 135.............................. THERAMEX: BUSINESS OVERVIEW
10.2.9 RELIANCE LIFE SCIENCES
・ TABLE 136............ RELIANCE LIFE SCIENCES: BUSINESS OVERVIEW
10.2.10 KASHIV BIOSCIENCES
・ TABLE 137.. KASHIV BIOSCIENCES: BUSINESS OVERVIEW
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, AND MNM VIEW (KEY STRENGTHS/RIGHT TO WIN, STRATEGIC CHOICES MADE, AND WEAKNESSES AND COMPETITIVE THREATS) MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
11.. APPENDIX